SOLICITATION NOTICE
B -- Study to provide data concerning the role of gene dose on chronic beryllium disease (CBD).
- Notice Date
- 5/26/2010
- Notice Type
- Presolicitation
- NAICS
- 611310
— Colleges, Universities, and Professional Schools
- Contracting Office
- Department of Health and Human Services, Centers for Disease Control and Prevention, Acquisition and Assistance Field Branch (Morgantown), 1095 Willowdale Road, Morgantown, West Virginia, 26505
- ZIP Code
- 26505
- Solicitation Number
- 000HCCHB-2010-84449
- Archive Date
- 7/11/2010
- Point of Contact
- Rebecca S Mullenax, Phone: 304-285-5880, Kimberly P Groves, Phone: 304-285-5885
- E-Mail Address
-
rmullenax@cdc.gov, kgroves@cdc.gov
(rmullenax@cdc.gov, kgroves@cdc.gov)
- Small Business Set-Aside
- N/A
- Description
- NOTICE OF INTENT TO ISSUE A PURCHASE ORDER. The Centers for Disease Control and Prevention (CDC), the National Institute for Occupational Safety and Health, ALOSH, Morgantown, WV, Health Effects Lab Division and the Pathology and Physiology Research Branch in collaboration with the Division of Respiratory Disease Studies hereby announces its intent to issue a purchase order to New York University for a study to provide data concerning the role of gene dose on chronic beryllium disease (CBD) in the transgenic mouse "knock-in" model that expresses the human HLA-DPB1 gene family. The project seeks to investigate the hypotheses: gene dose rather than exposure dose is the main determinant of severity of CD. Purpose: This research seeks to provide data concerning the role of gene dose on chronic beryllium disease in the transgenic mouse "knock-in" model that expresses the human HLA-DPB1 gene family, namely:, HLA-DPB1*0401 and HLA-DPB1*1701. The project investigates the hypothesis: gene dose rather than exposure dose is the main determinant of severity of chronic beryllium disease (CBD). This project seeks to investigate the contribution of homozygosity and heterozygosity for genes conferring increased susceptibility to CBD. The mice will be exposed to a single form of beryllium via pharyngeal aspiration. The outcome of the experiments will be measured by histopathological examination of the lung for a granulomatous response similar to that seen in CBD in humans (Frieman and Hardy, Human Pathology 1:25-44, 1970). These outcomes will be determined by PPRB scientists in HELD/NIOSH. Responsible sources that believe they possess the expertise and capabilities identified above are encouraged to submit to the Contracting Officer within 15 days from the posting date of this notice, their written capabilities statement and pricing information in the format they choose, not to exceed 10 pages. Please forward the capability statement and pricing information to Rebecca Mullenax, Purchasing Agent, Reference 000HCCHB-2010-84449, CDC NIOSH, 1095 Willowdale Road, Morgantown, WV 26505, or e-mail to RMULLENAX@CDC.GOV or FAX to 304-285-6083. Phone 304-285-5880. All vendors must be registered in the Central Contractor Registry (CCR) prior to an award of a federal contract. The website is: www.ccr.gov. The Government will review any/all capabilities statements and pricing information submitted and determine if other qualified sources do exist that could provide this requirement. Information received in response to this announcement will be used solely for the purpose of determining whether to conduct a competitive procurement. If no affirmative responses are received within 15 days, in accordance with FAR 13.106-1(b)(1), negotiations will be conducted with New York University, 70 Washington Square S, New York, NY 10012-1019 as the only source and a purchase order will be issued without any additional notices being posted.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/CDCP/MNIOSH/000HCCHB-2010-84449/listing.html)
- Record
- SN02161151-W 20100528/100526235350-baa11aad5c0afeae3ebc3020e9dc5c28 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |